TRSBF Stock Chart & Stats
$3.00
$0.10(14.49%)
At close: 4:00 PM EST
$3.00
$0.10(14.49%)
Day’s Range― - ―
52-Week Range$2.00 - $4.74
Previous CloseN/A
Volume313.00
Average Volume (3M)481.00
Market Cap
$5.23B
Enterprise Value$44.46K
Total Cash (Recent Filing)$19.73B
Total Debt (Recent Filing)$2.62B
Price to Earnings (P/E)4.3
Beta-1.58
Next Earnings
Aug 26, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend Yield1.48%
Share Statistics
EPS (TTM)3.41
Shares Outstanding2,538,084,500
10 Day Avg. Volume340
30 Day Avg. Volume481
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.97
Price to Sales (P/S)3.03
P/FCF Ratio5.88
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.65Price Target Upside54.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.13
Revenue Forecast (FY)$1.29B
Bulls Say, Bears Say
Bulls Say
Sharp 2025 Revenue UpswingA sustained ~90% revenue step-up in 2025 indicates meaningful commercial traction and faster product adoption in core therapeutic areas. Such a durable increase supports higher operating scale, better fixed-cost absorption and stronger reinvestment capacity for R&D and commercialization over the next 2–6 months.
Exceptionally High 2025 MarginsVery high gross and operating margins point to manufacturing efficiency and pricing power in biologics, implying structural competitive advantages (scale, proprietary processes, or differentiated products). Durable margin expansion enhances cash flow generation and funds clinical development and market expansion.
Strong Cash GenerationRobust operating and free cash flow near parity with net income signals high earnings quality and internal funding capacity. Durable cash generation supports debt reduction, capex, potential partnerships and resilience to funding risk, improving strategic optionality over multiple quarters.
Bears Say
Historic Performance VolatilityMaterial swings in revenue, margins and returns across prior years indicate outcomes can be binary around product cycles or one-off events. This makes forecasting and capital allocation harder, and raises the risk that 2025’s step-change may not persist, affecting medium-term planning and investor confidence.
Prior Weak Cash ConversionPeriods where operating cash lagged reported earnings highlight working-capital stress or timing issues. Recurrence would constrain free cash for R&D, M&A or dividends, and could force external financing or slow reinvestment during cyclical dips, undermining longer-term strategy execution.
Exposure To China Reimbursement PolicyRevenue and pricing are materially exposed to China’s reimbursement and centralized procurement mechanisms. Structural policy-driven price pressure or tender outcomes can compress margins and create revenue volatility across quarters, posing a persistent regulatory and market-access risk for the business model.
3SBio News
TRSBF FAQ
What was 3SBio’s price range in the past 12 months?
3SBio lowest stock price was $2.00 and its highest was $4.74 in the past 12 months.
What is 3SBio’s market cap?
3SBio’s market cap is $5.23B.
When is 3SBio’s upcoming earnings report date?
3SBio’s upcoming earnings report date is Aug 26, 2026 which is in 35 days.
How were 3SBio’s earnings last quarter?
3SBio released its earnings results on Mar 30, 2026. The company reported $0.429 earnings per share for the quarter, missing the consensus estimate of $0.533 by -$0.104.
Is 3SBio overvalued?
According to Wall Street analysts 3SBio’s price is currently Undervalued.
Does 3SBio pay dividends?
3SBio pays a Annually dividend of $0.032 which represents an annual dividend yield of 1.48%. See more information on 3SBio dividends here
What is 3SBio’s EPS estimate?
3SBio’s EPS estimate is 0.09.
How many shares outstanding does 3SBio have?
3SBio has 2,538,084,500 shares outstanding.
What happened to 3SBio’s price movement after its last earnings report?
3SBio reported an EPS of $0.429 in its last earnings report, missing expectations of $0.533. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of 3SBio?
Currently, no hedge funds are holding shares in TRSBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
3SBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
334.99%
12-Months-Change
Fundamentals
Return on Equity
1.48%
Trailing 12-Months
Asset Growth
56.38%
Trailing 12-Months
Company Description
3SBio
Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
TRSBF Stock 12 Month Forecast
Average Price Target
$4.65
▲(54.92% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Ownership Overview
―
Insiders
4.40% Mutual Funds
<0.01% Other Institutional Investors
89.36% Public Companies and
Individual Investors